Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

作者：Volkan Granit, Michael Benatar, Metin Kurtoğlu, Miloš D. Miljković, Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, Adam Slansky, Tuan Vu, Christopher M. Jewell, Michael S. Singer, Murat V. Kalayoglu, James F. Howard, James F Howard, Tahseen Mozaffar, Volkan Granit, Michael Benatar, Tahseen Mozaffar, Nizar Chahin, James F. Howard, James F. Howard, Adam D. Slansky, Marc H. Feinberg, Gregory Sahagian, Tuan Vu, Denise Pereira, Julie Steele, Maria Elena Paredes, Cara L. Benjamin, Krishna V. Komanduri, Ali A. Habib, Julia Kimberly Fong, Luis de la Cruz‐Merino, Diana Dimitrova, Manisha Chopra, Kelly Holley, Gabrielle DeMaria, April Tenorio, Naraly Requena, Beverly Mackanzie Brooks, Niraja Suresh, Jerrica Farias, Miloš D Miljković, Metin Kurtoglu, Minhtran Ngo Casi, Adam Chowdhury, Hafsa Kamboh, Charles A. Stewart, Mehmet Tosun, Yufei Shan, S. E. Daniel, Matthew T. Duvernay, Maria L. Kireeva, Emily English, Christopher M. Jewell, Michael S. Singer, Murat V. Kalayoglu · 发表于：The Lancet Neurology · 年份：2023 · DOI：10.1016/s1474-4422(23)00194-1 · 被引用次数：274 · 研究领域：CAR-T cell therapy research、Myasthenia Gravis and Thymoma、Monoclonal and Polyclonal Antibodies Research